155 related articles for article (PubMed ID: 33262201)
1. First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN.
Morfouace M; Stevovic A; Vinches M; Golfinopoulos V; Jin DX; Holmes O; Erlich R; Fayette J; Croce S; Ray-Coquard I; Girard N; Blay JY
ESMO Open; 2020 Dec; 5(6):e001075. PubMed ID: 33262201
[TBL] [Abstract][Full Text] [Related]
2. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
3. EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancers.
Tagliamento M; Morfouace M; Loizides C; Oliveira J; Greillier L; Raimbourg J; Toffart AC; Chatellier T; Cloarec N; Sullivan I; Brasiuniene B; Duruisseaux M; Oselin K; Robert MS; Fernandes C; Poncin A; Blay JY; Besse B; Girard N
NPJ Precis Oncol; 2024 Feb; 8(1):37. PubMed ID: 38366021
[TBL] [Abstract][Full Text] [Related]
4. Molecular profiling and precision medicine in rare gastrointestinal cancers within EURACAN in the SPECTA Arcagen study (EORTC-1843): too few patients with matched treatment in Europe.
Lamarca A; Morfouace M; Tejpar S; Oliveira J; Capela A; Penel N; Gennigens C; Brasiuniene B; Peron J; Stevovic A; Blay JY; Klümpen HJ
Ann Oncol; 2022 Nov; 33(11):1200-1202. PubMed ID: 35926814
[No Abstract] [Full Text] [Related]
5. Genomic Profiling of Sarcomas: A Promising Weapon in the Therapeutic Arsenal.
Lopes-Brás R; Lopez-Presa D; Esperança-Martins M; Melo-Alvim C; Gallego L; Costa L; Fernandes I
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430703
[TBL] [Abstract][Full Text] [Related]
6. The observational clinical registry (cohort design) of the European Reference Network on Rare Adult Solid Cancers: The protocol for the rare head and neck cancers.
Trama A; Licitra L; Cavalieri S; Bonfarnuzzo S; Baili P; Ciarfella A; Parente P; Almadori G; Ansarin M; Bacigalupo A; Baumeister P; Baujat B; Bossi P; Cavalera E; Cercato MC; Dieleman F; Fakhry N; Ferraresi V; Gaino F; Galizia D; Halamkova J; Halme E; Hardillo J; Hofauer B; Kinloch E; Livi L; Locati LD; Mattheis S; Mercante G; Mirabile A; Molteni G; Orlandi E; Persio R; Sciallero S; Smeele L; Tagliabue M; Valentini V; Van Harpen C; Westphalen CB; Botta L
PLoS One; 2023; 18(3):e0283071. PubMed ID: 36928072
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
8. Molecular Characterization of Ovarian Yolk Sac Tumor (OYST).
Hodroj K; Stevovic A; Attignon V; Ferraioli D; Meeus P; Croce S; Chopin N; Rossi L; Floquet A; Rousset-Jablonski C; Tredan O; Guyon F; Treilleux I; Rannou C; Morfouace M; Ray-Coquard I
Cancers (Basel); 2021 Jan; 13(2):. PubMed ID: 33435376
[TBL] [Abstract][Full Text] [Related]
9. EORTC SPECTA-AYA: A unique molecular profiling platform for adolescents and young adults with cancer in Europe.
de Rojas T; Kasper B; Van der Graaf W; Pfister SM; Bielle F; Ribalta T; Shenjere P; Preusser M; Fröhling S; Golfinopoulos V; Morfouace M; McCabe MG
Int J Cancer; 2020 Aug; 147(4):1180-1184. PubMed ID: 31465545
[TBL] [Abstract][Full Text] [Related]
10. Dysplastic Lipoma: A Distinctive Atypical Lipomatous Neoplasm With Anisocytosis, Focal Nuclear Atypia, p53 Overexpression, and a Lack of MDM2 Gene Amplification by FISH; A Report of 66 Cases Demonstrating Occasional Multifocality and a Rare Association With Retinoblastoma.
Michal M; Agaimy A; Contreras AL; Svajdler M; Kazakov DV; Steiner P; Grossmann P; Martinek P; Hadravsky L; Michalova K; Svajdler P; Szep Z; Michal M; Fetsch JF
Am J Surg Pathol; 2018 Nov; 42(11):1530-1540. PubMed ID: 30001242
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study.
Morfouace M; Horak P; Kreutzfeldt S; Stevovic A; de Rojas T; Denisova E; Hutter B; Bautista F; Oliveira J; Defachelles AS; White J; Kasper B; Preusser M; Golfinopoulos V; Pfister S; Van der Graaf W; Wardelmann E; Shenjere P; Fröhling S; McCabe MG
Eur J Cancer; 2023 Jan; 178():216-226. PubMed ID: 36470093
[TBL] [Abstract][Full Text] [Related]
12. Histiocytic and Dendritic Cell Sarcomas of Hematopoietic Origin Share Targetable Genomic Alterations Distinct from Follicular Dendritic Cell Sarcoma.
Massoth LR; Hung YP; Ferry JA; Hasserjian RP; Nardi V; Nielsen GP; Sadigh S; Venkataraman V; Selig M; Friedmann AM; Samore W; Killian JK; Milante R; Giessinger J; Foley-Peres K; Marcus C; Severson E; Duncan D; Sivakumar S; Ross JS; Desphande V; Ramkissoon SH; Vergilio JA; Louissaint A; Zukerberg LR; Williams EA
Oncologist; 2021 Jul; 26(7):e1263-e1272. PubMed ID: 33904632
[TBL] [Abstract][Full Text] [Related]
13. Three cases of rare salivary gland tumours: a molecular study of TP53, CDKN2A/ARF, RAS, BRAF, PTEN, MAPK2 and EGFR genes.
Falbo V; Floridia G; Censi F; Marra M; Foschini MP; Taruscio D
Oncol Rep; 2011 Jul; 26(1):3-11. PubMed ID: 21503581
[TBL] [Abstract][Full Text] [Related]
14. "Cancer 2015": A Prospective, Population-Based Cancer Cohort-Phase 1: Feasibility of Genomics-Guided Precision Medicine in the Clinic.
Parisot JP; Thorne H; Fellowes A; Doig K; Lucas M; McNeil JJ; Doble B; Dobrovic A; John T; James PA; Lipton L; Ashley D; Hayes T; McMurrick P; Richardson G; Lorgelly P; Fox SB; Thomas DM
J Pers Med; 2015 Oct; 5(4):354-69. PubMed ID: 26529019
[TBL] [Abstract][Full Text] [Related]
15. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Marabelle A; Fakih M; Lopez J; Shah M; Shapira-Frommer R; Nakagawa K; Chung HC; Kindler HL; Lopez-Martin JA; Miller WH; Italiano A; Kao S; Piha-Paul SA; Delord JP; McWilliams RR; Fabrizio DA; Aurora-Garg D; Xu L; Jin F; Norwood K; Bang YJ
Lancet Oncol; 2020 Oct; 21(10):1353-1365. PubMed ID: 32919526
[TBL] [Abstract][Full Text] [Related]
16. Clinical Application of the FoundationOne CDx Assay to Therapeutic Decision-Making for Patients with Advanced Solid Tumors.
Takeda M; Takahama T; Sakai K; Shimizu S; Watanabe S; Kawakami H; Tanaka K; Sato C; Hayashi H; Nonagase Y; Yonesaka K; Takegawa N; Okuno T; Yoshida T; Fumita S; Suzuki S; Haratani K; Saigoh K; Ito A; Mitsudomi T; Handa H; Fukuoka K; Nakagawa K; Nishio K
Oncologist; 2021 Apr; 26(4):e588-e596. PubMed ID: 33325566
[TBL] [Abstract][Full Text] [Related]
17. Clinical application of genomic profiling to find druggable targets for adolescent and young adult (AYA) cancer patients with metastasis.
Cha S; Lee J; Shin JY; Kim JY; Sim SH; Keam B; Kim TM; Kim DW; Heo DS; Lee SH; Kim JI
BMC Cancer; 2016 Feb; 16():170. PubMed ID: 26925973
[TBL] [Abstract][Full Text] [Related]
18. Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN.
Blay JY; Casali P; Ray-Coquard I; Seckl MJ; Gietema J; de Herder WW; Caplin M; Klümpen HJ; Glehen O; Wyrwicz L; Peeters R; Licitra L; Girard N; Piperno-Neumann S; Kapiteijn E; Idbaih A; Franceschi E; Trama A; Frezza AM; Hohenberger P; Hindi N; Martin-Broto J; Schell J; Rogasik M; Lejeune S; Oliver K; de Lorenzo F; Weinman A
Lancet Reg Health Eur; 2024 Apr; 39():100861. PubMed ID: 38384730
[TBL] [Abstract][Full Text] [Related]
19. Patients with Rare Cancers in the Drug Rediscovery Protocol (DRUP) Benefit from Genomics-Guided Treatment.
Hoes LR; van Berge Henegouwen JM; van der Wijngaart H; Zeverijn LJ; van der Velden DL; van de Haar J; Roepman P; de Leng WJ; Jansen AML; van Werkhoven E; van der Noort V; Huitema ADR; Gort EH; de Groot JWB; Kerver ED; de Groot DJ; Erdkamp F; Beerepoot LV; Hendriks MP; Smit EF; van der Graaf WTA; van Herpen CML; Labots M; Hoeben A; Morreau H; Lolkema MP; Cuppen E; Gelderblom H; Verheul HMW; Voest EE
Clin Cancer Res; 2022 Apr; 28(7):1402-1411. PubMed ID: 35046062
[TBL] [Abstract][Full Text] [Related]
20. Sarcomas and malignant phyllodes tumours of the breast--a retrospective study.
Confavreux C; Lurkin A; Mitton N; Blondet R; Saba C; Ranchère D; Sunyach MP; Thiesse P; Biron P; Blay JY; Ray-Coquard I
Eur J Cancer; 2006 Nov; 42(16):2715-21. PubMed ID: 17023158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
